Premium
Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls
Author(s) -
Agalliu Ilir,
Ortega Roberto A.,
Luciano Marta San,
Mirelman Anat,
PontSunyer Claustre,
Brockmann Kathrin,
Vilas Dolores,
Tolosa Eduardo,
Berg Daniela,
Warø Bjørg,
Glickman Amanda,
Raymond Deborah,
Inzelberg Rivka,
RuizMartinez Javier,
Mondragon Elisabet,
Friedman Eitan,
HassinBaer Sharon,
Alcalay Roy N.,
MejiaSantana Helen,
Aasly Jan,
Foroud Tatiana,
Marder Karen,
Giladi Nir,
Bressman Susan,
SaundersPullman Rachel
Publication year - 2019
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.27807
Subject(s) - lrrk2 , medicine , odds ratio , parkinson's disease , cancer , confidence interval , disease , gastroenterology , colorectal cancer , oncology , leukemia
Background Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 ( LRRK2 ) G2019S mutation ( LRRK2‐ PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods Cancer outcomes were compared among 257 LRRK2‐ PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed‐effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2‐ PD and 1946 IPD patients. Results Although cancer prevalence was similar among LRRK2 ‐PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2‐ PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2‐ PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions The increased risks of leukemia as well as skin and colon cancers among LRRK2‐ PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society